X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs MYLAN (US) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   MYLAN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
MYLAN
Dec-14
GLENMARK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs9304,254-   
Low Rs5172,998-   
Sales per share (Unadj.) Rs322.61,456.2-  
Earnings per share (Unadj.) Rs28.5175.4-  
Cash flow per share (Unadj.) Rs39.2282.4-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.0723.9-  
Shares outstanding (eoy) m282.17378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x2.22.5 90.1%   
Avg P/E ratio x25.420.7 122.9%  
P/CF ratio (eoy) x18.512.8 143.8%  
Price / Book Value ratio x4.05.0 79.0%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,2061,371,817 14.9%   
No. of employees `00013.725.0 54.9%   
Total wages/salary Rs m18,7180-   
Avg. sales/employee Rs Th6,636.822,039.1 30.1%   
Avg. wages/employee Rs Th1,364.70-   
Avg. net profit/employee Rs Th586.12,655.0 22.1%   
INCOME DATA
Net Sales Rs m91,031550,976 16.5%  
Other income Rs m914-3,212 -28.5%   
Total revenues Rs m91,945547,765 16.8%   
Gross profit Rs m16,154137,030 11.8%  
Depreciation Rs m3,01940,467 7.5%   
Interest Rs m2,85623,766 12.0%   
Profit before tax Rs m11,19369,586 16.1%   
Minority Interest Rs m0-285 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1552,926 107.8%   
Profit after tax Rs m8,03966,374 12.1%  
Gross profit margin %17.724.9 71.4%  
Effective tax rate %28.24.2 670.2%   
Net profit margin %8.812.0 73.3%  
BALANCE SHEET DATA
Current assets Rs m69,887484,381 14.4%   
Current liabilities Rs m32,879378,689 8.7%   
Net working cap to sales %40.719.2 211.9%  
Current ratio x2.11.3 166.2%  
Inventory Days Days8178 104.3%  
Debtors Days Days93107 87.2%  
Net fixed assets Rs m28,892127,467 22.7%   
Share capital Rs m28219,484 1.4%   
"Free" reserves Rs m51,3530-   
Net worth Rs m51,635273,890 18.9%   
Long term debt Rs m41,418409,164 10.1%   
Total assets Rs m125,9541,103,202 11.4%  
Interest coverage x4.93.9 125.2%   
Debt to equity ratio x0.81.5 53.7%  
Sales to assets ratio x0.70.5 144.7%   
Return on assets %8.68.2 105.9%  
Return on equity %15.624.2 64.2%  
Return on capital %15.113.6 110.8%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m26,5980-   
CASH FLOW
From Operations Rs m16,48172,426 22.8%  
From Investments Rs m-10,133-57,117 17.7%  
From Financial Activity Rs m-4,685-19,084 24.5%  
Net Cashflow Rs m1,770-3,775 -46.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.37 Rs / USD

Compare GLENMARK PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: VENUS REMEDIES  PLETHICO PHARMA  LUPIN LTD  SUN PHARMA  DR. DATSONS LABS  



Today's Market

Sensex Ends Day in Red, Oil Prices, and Top Stocks in Action Today(Pre-Open)

Share markets in India witnessed most of the selling pressure during closing hours yesterday and ended their trading session on a negative note.

Related Views On News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Nov 21, 2018 09:25 AM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - WYETH LTD COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS